Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning.

Lochner A, Marais E, Genade S, Huisamen B, du Toit EF, Moolman JA.

Cardiovasc J Afr. 2009 Jan-Feb;20(1):43-51. Review.

2.

Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK.

Moolman JA, Hartley S, Van Wyk J, Marais E, Lochner A.

Cardiovasc Drugs Ther. 2006 Feb;20(1):13-25.

PMID:
16552474
3.

p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning.

Marais E, Genade S, Strijdom H, Moolman JA, Lochner A.

J Mol Cell Cardiol. 2001 Dec;33(12):2157-77.

PMID:
11735262
4.

CREB activation and ischaemic preconditioning.

Marais E, Genade S, Lochner A.

Cardiovasc Drugs Ther. 2008 Feb;22(1):3-17. doi: 10.1007/s10557-007-6078-3. Epub 2008 Jan 20.

PMID:
18205034
5.

Kinases and phosphatases in ischaemic preconditioning: a re-evaluation.

Fan WJ, van Vuuren D, Genade S, Lochner A.

Basic Res Cardiol. 2010 Jul;105(4):495-511. doi: 10.1007/s00395-010-0086-3. Epub 2010 Feb 2.

PMID:
20127248
6.

Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model.

du Toit EF, Genade S, Carlini S, Moolman JA, Brunner F, Lochner A.

Eur J Pharmacol. 2007 Feb 5;556(1-3):115-20. Epub 2006 Nov 10.

PMID:
17157294
7.

The significance of the washout period in preconditioning.

Salie R, Lochner A, Loubser DJ.

Cardiovasc Ther. 2017 Jun;35(3). doi: 10.1111/1755-5922.12252.

PMID:
28118517
8.
9.

Myocardial triggers involved in activation of remote ischaemic preconditioning.

Donato M, Goyeneche MA, Garces M, Marchini T, Pérez V, Del Mauro J, Höcht C, Rodríguez M, Evelson P, Gelpi RJ.

Exp Physiol. 2016 Jun 1;101(6):708-16. doi: 10.1113/EP085535. Epub 2016 May 1.

10.

Role of cyclic nucleotide phosphodiesterases in ischemic preconditioning.

Lochner A, Genade S, Tromp E, Opie L, Moolman J, Thomas S, Podzuweit T.

Mol Cell Biochem. 1998 Sep;186(1-2):169-75.

PMID:
9774198
11.

The role of β-adrenergic receptors in the cardioprotective effects of beta-preconditioning (βPC).

Salie R, Moolman JA, Lochner A.

Cardiovasc Drugs Ther. 2011 Feb;25(1):31-46. doi: 10.1007/s10557-010-6275-3.

PMID:
21225332
12.

Effects of hydrogen sulphide on ischaemia-reperfusion injury and ischaemic preconditioning in the isolated, perfused rat heart.

Bliksøen M, Kaljusto ML, Vaage J, Stensløkken KO.

Eur J Cardiothorac Surg. 2008 Aug;34(2):344-9. doi: 10.1016/j.ejcts.2008.03.017. Epub 2008 May 5.

PMID:
18455926
13.

Myocardial adenosine does not correlate with the protection mediated by ischaemic or pharmacological preconditioning in rat heart.

Vasara E, Katharou I, Lazou A.

Clin Exp Pharmacol Physiol. 2003 May-Jun;30(5-6):350-6.

PMID:
12859425
14.

The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning.

Marais E, Genade S, Salie R, Huisamen B, Maritz S, Moolman JA, Lochner A.

Basic Res Cardiol. 2005 Jan;100(1):35-47. Epub 2004 Nov 3.

PMID:
15526116
15.
16.
18.
19.

Myocardial susceptibility to ischaemia/reperfusion in obesity: a re-evaluation of the effects of age.

Webster I, Salie R, Marais E, Fan WJ, Maarman G, Huisamen B, Lochner A.

BMC Physiol. 2017 Mar 17;17(1):3. doi: 10.1186/s12899-017-0030-y.

20.

High carbohydrate and high fat diets protect the heart against ischaemia/reperfusion injury.

Salie R, Huisamen B, Lochner A.

Cardiovasc Diabetol. 2014 Jul 18;13:109. doi: 10.1186/s12933-014-0109-8.

Supplemental Content

Support Center